A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE)

Affiliation auteurs!!!! Error affiliation !!!!
TitreA Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Dexamethasone (Vd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE)
Type de publicationJournal Article
Year of Publication2019
AuteursMoreau P, Attal M, Facon T, Caillot D, Lenain P, Benboubker L, Lam A, Krotneva S, Proskorovsky I, Kampfenkel T, Vanquickelberghe V, Cote S, Sonneveld P
JournalCLINICAL LYMPHOMA MYELOMA & LEUKEMIA
Volume19
PaginationE200-E201
Date PublishedOCT
Type of ArticleMeeting Abstract
ISSN2152-2650
Mots-clésautologous stem cell transplant, daratumumab, Newly diagnosed multiple myeloma
DOI10.1016/j.clml.2019.09.334